EXCHANGE TRANSFUION IN HEMOLYTIC DISEASE OF NEWBORN:EFFICACY OF WHOLE BLOOD RECONSTITUTED (WBR) OVER WHOLE BLOOD-Reference-Cited by-同舟云学术

EXCHANGE TRANSFUION IN HEMOLYTIC DISEASE OF NEWBORN:EFFICACY OF WHOLE BLOOD RECONSTITUTED (WBR) OVER WHOLE BLOOD

Published:2021-04-01 Issue: Volume: Page:62-65
ISSN:
Container-title:INTERNATIONAL JOURNAL OF SCIENTIFIC RESEARCH
language:en
Short-container-title:ijsr

Author:

Kaur Diljeet¹,Jain Arun²,Pal Singh Gajendra³,Mangal K.S⁴

Affiliation:

1. Post Graduate, Department of Pathology, Gajraraja Medical College, Gwalior, Madhya Pradesh.

2. Associate Professor, Department of Pathology, Gajraraja Medical College, Gwalior, Madhya Pradesh

3. Assistant Professor, Department of Pathology, Gajraraja Medical College, Gwalior, Madhya Pradesh.

4. Professor Head of Department, Department Of Pathology, Gajraraja Medical College, Gwalior, Madhya Pradesh.

Abstract

INTRODUCTION: hemolytic disease of newborn; also known as erythroblastosis fetalis, is an preventable blood group disorder that occurs when the blood types of mother and fetus are incompatible. A prospective study was MATERIAL AND METHOD: carried out on the cases suffering with HDN in the year 2018-2020 in the Blood Bank of the Department of Pathology, G.R. Medical College, Gwalior. The affected cases were given double volume exchange transfusion by reconstituted blood or whole blood and the outcome was studied. 150 cases of HDN RESULT: were studied out of which RhD HDN was found to be the most common cause seen in 61.3% and exchange transfusion by reconstituted blood was found to be an effective therapy. The reconstituted blood is found to be immunologicall CONCLUSION: y much safer and better than whole blood for purpose of exchange transfusion in hemolytic disease of fetus and newborn because of its superiority in minimizing transfusion reactions and in achieving all the therapeutic effects of exchange transfusion in better way.

Publisher

World Wide Journals

Reference23 articles.

1. Hadley AG. Laboratory assays for predicting the severity of haemolytic disease of the fetus and newborn. Transpl Immunol. 2002;10:191–8.

2. Petrova A, Mehta R, Birchwood G, Ostfeld B, Hegyi T. Management of neonatal hyperbilirubinemia: Pediatricians Practices and educational needs. BMC Pediatr. 2006;6:6.

3. Liumbruno GM, D'Alessandro A, Rea F, et al; The role of antenatal immunoprophylaxis in the prevention of maternal-foetal anti-Rh(D) alloimmunisation. Blood Transfus. 2010 Jan;8(1):8-16. doi: 10.2450/2009.0108-09.

4. Roberts IA; The changing face of haemolytic disease of the newborn. Early Hum Dev. 2008 Aug;84(8):515-23. doi: 10.1016/j.earlhumdev.2008.06.005. Epub 2008 Jul 14.

5. Kaplan M, Na'amad M, Kenan A et al. Failure to predict hemolysis and hyperbilirubinemia by IgG subclass in blood group A or B infants born to group O mothers. Pediatrics, 123(1), 2009, e132-7.